RecruitingNCT06314529

Long-term Follow-up Study of BHC001 for TDT

Long-term Follow-up Study of BHC001 in the Treatment of Transfusion-dependent β-thalassemia

Sponsor

Bioray Laboratories

Enrollment

6 participants

Start Date

Dec 14, 2022

Study Type

OBSERVATIONAL

Summary

Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.

Min Age: 5 YearsMax Age: 35 Years

Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.

Interested in this trial?

Get notified about updates and connect with the research team.

OTHERAssessments

Safety and efficacy assessments

The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

Nanning, Guangxi, China

Xiangya Hospital of Central South University

Changsha, Hunan, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

NCT06314529